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BACKGROUND: The Islet Autoantibody Standardization
Program (IASP) aims to improve the performance of im-
munoassays measuring type 1 diabetes (T1D)-associated
autoantibodies and the concordance of results among
laboratories. IASP organizes international interlabora-
tory assay comparison studies in which blinded serum
samples are distributed to participating laboratories, fol-
lowed by centralized collection and analysis of results,
providing participants with an unbiased comparative as-
sessment. In this report, we describe the results of glu-
tamic acid decarboxylase autoantibody (GADA) assays
presented in the IASP 2018 workshop.
METHODS: In May 2018, IASP distributed to partici-
pants uniquely coded sera from 43 new-onset T1D pa-
tients, 7 multiple autoantibody-positive nondiabetic in-
dividuals, and 90 blood donors. Results were analyzed for
the following metrics: sensitivity, specificity, accuracy,
area under the ROC curve (ROC-AUC), partial ROC-
AUC at 95% specificity (pAUC95), and concordance of
qualitative and quantitative results.
RESULTS: Thirty-seven laboratories submitted results
from a total of 48 different GADA assays adopting 9
different formats. The median ROC-AUC and pAUC95
of all assays were 0.87 [interquartile range (IQR), 0.83–
0.89] and 0.036 (IQR, 0.032–0.039), respectively. Large
differences in pAUC95 (range, 0.001–0.0411) were ob-
served across assays. Of formats widely adopted, bridge
ELISAs showed the best median pAUC95 (0.039; range,
0.036–0.041).
CONCLUSIONS: Several novel assay formats submitted to
this study showed heterogeneous performance. In 2018,
the majority of the best performing GADA immunoas-
says consisted of novel or established nonradioactive tests
that proved on a par or superior to the radiobinding
assay, the previous gold standard assay format for GADA
measurement.
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The Islet Autoantibody Standardization Program (IASP)8
is a collaborative effort aimed at improving the perfor-
mance of assays measuring type 1 diabetes (T1D)-
associated autoantibodies and the concordance of results
between laboratories (1 ).
IASP is supported by the Immunology of Diabetes
Society (IDS) and the NIH, coordinated by an IDS-
nominated committee, and run by theUniversity of Flor-
ida Pathology Laboratories, Endocrine Autoantibody
Laboratory.
IASP organizes international interlaboratory com-
parison studies in which blinded T1D and control
serum samples are tested for T1D-associated autoan-
tibodies by participating laboratories. Centralized col-
lection and analysis of results by the IASP committee
provide participants with an unbiased comparison of
assay performance. Moreover, IASP fosters the contin-
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uous improvement of T1D autoantibody immunoas-
says through the dissemination of empirically tested
best practice protocols, state-of-the-art reagents, and
serum standards.
In this report, we analyze the results of assays for
antibodies to glutamic acid decarboxylase 65 (GADA)
(2 ) submitted in 2018 to the IASP interlaboratory com-
parison study and presented at the IASP 2018 workshop
held at the 16th Immunology of Diabetes Society Con-
gress in London, UK.
GADAs are found in several neurological and endo-
crine autoimmune diseases (3–5 ). In the setting of auto-
immune diabetes, GADAs are the most prevalent auto-
antibody at onset of T1D and the hallmark of latent
autoimmune diabetes in adults (6 ), a slowly progressing
form of pancreatic endocrine autoimmunity affecting up
to 5% of type 2 diabetes patients. Moreover, GADA
measurement is a cornerstone of screening strategies for
T1D (7 ).
Themost recent IASPGADA interlaboratory compar-
ison and standardization study took place in 2018, with 37
laboratories from 17 countries in North America, Europe,
Asia, and Australia submitting results from 48 different
GADA assays, based on 9 different assay formats, after test-
ing blinded samples from 50 cases with T1D or multiple
islet autoimmunity and 90 blood donors.
Materials and Methods
STUDY DESIGN
In the 2018 IASP interlaboratory comparison study, par-
ticipants received sets of the same serum samples consist-
ing of 50 cases (43 sera from new-onset T1D patients and
7 multiple islet autoantibody-positive first-degree rela-
tives of T1D patients enrolled in the TrialNet Ancillary
Study—Pathway to Prevention, who during screening
showed a transiently altered glucose tolerance test), 90
control samples (all blood donors), and 10 additional
samples to be used for substudies unrelated to GADA
testing.
The T1D patients had a median age of 14 years
(range, 8–47 years) and included 15 females and 28
males, of whom 37 were white, 2 black, 2 of mixed race,
and 2 of undisclosed ancestry. The multiple T1D
autoantibody-positive participants had a median age of
16 years (range, 12–53 years) and included 4 females and
3 males, all of white ancestry. The blood donors had a
median age of 20 years (range, 18–30 years) and included
44 females and 44 males, of whom 69 were white, 19
black, and 2 for whom demographic data were not
available.
New-onset T1D samples were contributed by sev-
eral centers around the world and collected within 14
days of starting insulin treatment. Blood donor samples
were collected in the US and included only people with-
out diabetes. All serum samples submitted to the IASP
repository were collected upon obtaining written in-
formed consent and with the approval of local ethics
committees as required by local regulations according to
the ethical principles for medical research involving hu-
man participants of the Declaration of Helsinki.
All sera were labeled and distributed as blinded
105-L frozen aliquots, labeled with an aliquot-specific
unique code. Laboratories were free to use any GADA
assay format but were asked to provide details of their
assay protocol and to report assay results, including raw
data, to IASP for analysis using uniform Excel (Mi-
crosoft) reporting sheets.
DATA ANALYSIS
We calculated sensitivity and specificity for each assay as
the percentage of case sera reported as GADA-positive
and as the percentage of blood donor sera reported as
negative, respectively.
Adjusted sensitivity 95, i.e., the level of sensitivity cor-
responding to a specificity of 95%, was derived by placing
the threshold for positivity at the 95th percentile of values
observed in the blood donor samples in each assay.
Concordance of laboratory-assigned positive or neg-
ative scores across assays was expressed as average pairwise
percent agreement between assays (APPA), i.e., the aver-
age number of times each possible combination of 2 as-
says agreed onGADA-positive/negative scores divided by
the number of samples scored. We tested the occurrence
of agreement by pure chance by calculating the first
agreement coefficient (AC1) according to Gwet (8, 9 )
and the  coefficient according to Fleiss (10) using the
corresponding functions (http://agreestat.com/r_functions.
html; Advanced Analytics) in the R language and environ-
ment for statistical computing and graphics (11).
Assay performance in discriminating health from
disease was analyzed using the area under the ROC curve
(ROC-AUC) and the partial ROC-AUC imposing a
specificity 95% (pAUC95) (12 ).
The analysis of interassay antibody titer concor-
dance was performed after ranking of patient and control
samples according to autoantibody levels in each assay by
calculating the Kendall W rank correlation coefficient (13)
using the vegan R package (https://CRAN.R-project.
org/packagevegan). The significance of differences in
mean ranking of selected cases between hybrid solid/
liquid phase vs liquid phase-only assays was tested using
the Mann–Whitney test. This synthetic index based on
ranking was preferred to classical pairwise regression
analysis in light of the numerous comparisons to be made
and to the presence of systematic differences in measure-
ment of high and low GADA titers across assays, mostly
related to the adoption of a variety of alternative algo-
rithms for calculating local arbitrary units.
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For laboratories that reported results in WHO units
(14 ), the concordance of antibody titers was evaluated by
calculating the overall concordance correlation coeffi-
cient (OCCC) according to Barnhart (15 ) using the
f.analysis macro (16 ). The OCCC measures how far the
fitted linear relationship of 2 variables x and y deviates
from the concordance line (accuracy) and how far each
observation deviates from the fitted line (precision) and
ranges from 0 to1, where results close to1 stand for
near perfect concordance (or perfect discordance) and 0
stands for no correlation.
For all statistical analyses, 2-tailed P values 0.05
were considered as significant.
Results
SUMMARY OF SUBMITTED GADA ASSAY FORMATS
Forty-one laboratories from 17 countries inNorth Amer-
ica, Europe, Asia, and Australia registered for the
IASP2018 interlaboratory comparison study. Of the par-
ticipating laboratories, 37 submitted results (see Appen-
dix 1 in the Data Supplement that accompanies the on-
line version of this article at http://www.clinchem.org/
content/vol65/issue9) from a total of 48 different GADA
assays using 9 different formats.
The submitted assays adopted the following for-
mats: radiobinding assay (RBA) (18 assays, 37.5%) (17 );
bridge-ELISA (12 assays, 25.0%) (18 ); luciferase immu-
noprecipitation system (LIPS) (8 assays, 16.7%) (19 );
electrochemiluminescence (ECL) (3 assays, 6.3%, of
which 1 multiplexed individual GADA measurement of
the IgG, IgA, and IgM immunoglobulin classes) (20 );
chemiluminescence immunoassay (CLIA) (2 assays,
4.2%, of which 1 used a bridge format); Luminex bead
immunoassay (LBI) (2 assays, 4.2%); multiplex plas-
monic near-infrared fluorescence (MPNIRF) (1 assay,
2.1%) (21 ); multiplex fluorescence energy transfer
(MFRET) (1 assay, 2.1%); and antibody-dependent ag-
glutination PCR (ADAP) (1 assay, 2.1%) (22 ). Antigen–
antibody binding occurred in liquid phase in 29 assays
(ADAP, ECL, LIPS, RBA) followed by the capture of
immune complexes either through the recovery of immu-
noglobulins (LIPS, RBA) or tagged antigen (ECL), in
hybrid solid/liquid phase in 13 assays (bridge-ELISA and
CLIA), solid phase in 3 assays (LBI andMPNIRF), while
binding phase was not specified for 1 assay (MFRET).
Major characteristics and metrics of each individual assay
are reported in Table 1 of the online Data Supplement.
Among RBAs, 5 assays adopted the National Insti-
tute of Diabetes and Digestive and Kidney Diseases (NI-
DDK) harmonized protocol (23 ) and 4 used truncated
GAD65 antigens (24–26). Most RBAs used glutamic
acid decarboxylase antigens transcribed and translated in
vitro (17of 18 assays) and radiolabeledwith 35S or 3H (in16
and 1 case, respectively). One assay used 125I iodinated re-
combinant GAD65 antigen. Results in WHO units (14)
were reported for all bridge-ELISA assays, 5 RBAs, and 3
LIPS that used digestive and kidney unit (DK) standards
(23). Among LIPS, 7 assays used the Nanoluc and 1 used
the Renilla luciferase reporters.Most LIPS assays used trun-
cated GAD65 antigens corresponding to glutamic acid de-
carboxylase amino acids 96 to 585 (GAD96–585, 4 assays)
or 188 to 585 (GAD188–585, 2 assays) instead of full-
length GAD65 (GAD1–585, 1 assay).
ASSAY SENSITIVITY, SPECIFICITY, AND ACCURACY
The median laboratory-assigned assay sensitivity, speci-
ficity, and accuracy were 69% [interquartile range (IQR),
64%–76%], 98.9% (IQR, 96.7%–100%), and 88.6%
(IQR, 84.5%–90.7%), respectively (Table 1 and Fig. 1
here and also Table 1 in the online Data Supplement).
ASSAY PERFORMANCE
Themedian ROC-AUCwas 0.87 (IQR, 0.83–0.89) (see
Table 1 here and also Table 1 and Fig. 1 in the online
Data Supplement). As a more relevant proxy of assay
performance based around commonly adopted thresh-
olds for positivity, we calculated also the pAUC95. The
median of pAUC95 GADA assays was 0.036 (IQR,
0.032–0.039) against a theoretical maximum of 0.05,
and the stratification according to format highlighted a
wide heterogeneity of performance across both assays and
formats when high specificity was levied (Fig. 2 here and
also Fig. 2 in the online Data Supplement).
The median pAUC95 of RBAs was 0.0349 (range,
0.0253–0.0394). The RBAs with pAUC95 above the
overall median included assays using a truncated GAD65
antigen corresponding to amino acids 96 to 585 (4 of 4
assays), RBAs using the NIDDK harmonized protocol (2
of 5 assays), and only 2 RBAs using local protocols and
full-length GAD65 (2 of 8 assays).
Bridge-ELISA assays’ pAUC95 showed a median
value of 0.0393 (range, 0.0358–0.0411), always at or
above the median of all assays.
ECL assays that, like the bridge-ELISA, are theoret-
ically capable of detecting autoantibodies of any immu-
noglobulin class showed a pAUC95 of 0.0362 (range,
0.0347–0.0377). A third ECL assay aimed to multiplex
the measurement of specific GADA immunoglobulin
classes (IgG, IgM, and IgA) and showed variable
pAUC95 (ECL-IgG pAUC95  0.0304, ECL-IgM
pAUC95 0.0160, and ECL-IgA pAUC95 0.0120).
LIPS assays using a truncated antigen corresponding to
GAD65 amino acids 96 to 585 and a nanoluciferase re-
porter showed a median pAUC95 of 0.0360 (range,
0.0359–0.0368), whereas the LIPS using a Renilla lu-
ciferase reporter showed lower performance (pAUC95 
0.0196). A LIPS assay using full-length GAD65 showed a
pAUC95 of 0.034, and 2 LIPS assays using a truncated
IASP2018 GAD65 Autoantibody Interlaboratory Comparison
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antigen corresponding to GAD65 amino acids 188 to 585
had a median pAUC95 of 0.034 (range, 0.034 to 0.035).
Among assays that used formats submitted for the
first time to the IASP interlaboratory comparison
study, the best performance was achieved by the
ADAP assay (pAUC95  0.0411), followed by 2 as-
says using the CLIA format with a median pAUC95
of 0.035 (range, 0.031–0.038), whereas a poorer per-
formance was observed for the 3 remaining assays
adopting the MPNIRF (pAUC95  0.014), LBI
(pAUC95 0.006), andMFRET (pAUC95 0.001)
formats, respectively.
CONCORDANCE OF LABORATORY-ASSIGNED
POSITIVE/NEGATIVE SCORES
In cases, the APPA of positive/negative scores across all
assays was 83.16% and the first-order agreement coeffi-
cient AC1 (9 ) was 0.69. Concordance increased when
the analysis was limited to assays with pAUC95 above the
median (APPA 90.82%; AC1 0.85) or when assays
using the same format and/or antigens were compared
(APPA range  84.0%–96.31%; AC1 range  0.73–
0.94) (see Table 2 in the online Data Supplement).
In control samples, the APPA and AC1 coefficient
across all assays were 96.10% and 0.96, respectively.
Similar to cases, both agreement measures increased
when assays with pAUC95 above the median (APPA 
97.52%; AC1  0.97) or assays using the same format
and/or antigens were compared (APPA range 93.3%–
98.2%; AC1 range  0.92–0.98) with the exception of
ECL and CLIA assays (see Table 3 in the online Data
Supplement).
The results of the Fleiss  concordance coefficient
(10 ), an alternative metric of agreement, were invariably
lower (range, 0.03 to 0.49), an observation consistent
with the majority of control samples being scored
Fig. 1. Scatter plots of sensitivity and specificity of GADA assays based on laboratory-assignedGADA-positive or -negative scores for
50 cases and 90 controls.
Filled circles stand for individual assays. Dashed linesmark themedian sensitivity and specificity of all assays. Assays are categorized according
to format and its variants. Categories are sorted by their median assay performance.
IASP2018 GAD65 Autoantibody Interlaboratory Comparison
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GADA-positive sporadically in only a small fraction of
assays (27 ).
The analysis of laboratory-assigned positive/nega-
tive scores highlighted the existence of format-associated
patterns. A subset of cases was recognized as GADA-
positive predominantly by ADAP and bridge-ELISA as-
says (samples IDS324, IDS309, IDS290, IDS312, and
IDS337) and to a lower extent by some ECL (samples
IDS309, IDS290, IDS312, and IDS337) or LIPS assays
(samples IDS312 and IDS337) but not by themajority of
RBAs (Fig. 3). Conversely, a subset of controls was rec-
ognized as GADA-positive exclusively by a minority of
RBAs (samples TS23727, N59416, and N53371) or
LIPS assays (sample S8650) (Fig. 4).
To evaluate the impact of local threshold selection
criteria on assay sensitivity and specificity, the data were
reanalyzed after imposing a 95% specificity onto
IASP2018 controls. The newly assigned positive/nega-
tive scores highlighted an improved concordance be-
tween bridge-ELISAs or ECLs and RBAs or LIPS, with
all samples previously recognized as positives exclusively
by the hybrid solid/liquid phase bridge-ELISA format
scoring positive also in liquid phase assays (see Fig. 3 in
the online Data Supplement). In control samples, the use
of these novel thresholds made more apparent the pres-
ence of weak format and/or antigen-specific reactivities
that lead to frequent positive scores for subsets of control
samples in local or harmonized protocol RBAs (samples
TS23727, N59416, and N53371) and RBAs or LIPS
assays using truncated GAD96–585 (samples LQ23340,
N59534, and S8650) (see Fig. 4 in the online Data
Supplement).
CONCORDANCE OF AUTOANTIBODY TITER RANKS
The interassay concordance of antibody titer was eval-
uated by first ranking sera in each assay (Fig. 5A here
and also Figs. 5 and 6 in the online Data Supplement)
followed by calculation of the Kendall W ranking
agreement coefficient (13 ). The W coefficients across
all assays were 0.80 and 0.13 in cases and control
samples, respectively (see Tables 2 and 3 in the online
Data Supplement).
The exclusion from the analysis of assay formats
with the 4 lowest pAUC95 led to amodest increase of the
agreement coefficient in both cases and controls (W, 0.85
and 0.14, respectively), while limiting the analysis to
assays with performance above the overall median
pAUC95 showed again an increase of W in cases (W 
0.93) but only amarginal improvement in controls (W
0.15), suggesting that higher concordance in cases was
partially correlated with assay performance.
Concordance of GADA titer ranks increased among
assays using the same format both in cases and, at least for
assays other than the bridge-ELISA, also in control sam-
ples (see Tables 2 and 3 and Figs. 5 and 6 in the online
Data Supplement).
Amarginal increase ofW in cases after excluding assays
measuring only IgM or IgA antibodies (W  0.82) was
observed, indicating that discrepancies of GADA titer ranks
across assays were not exclusively associated with measure-
ment of immunoglobulins of a class other than IgG.
Stratification of assays according to antibody/antigen
binding in hybrid solid/liquid phase, i.e., bridge-ELISAs, or
liquid phase, i.e., including ECL, RBA, and LIPS, high-
lighted a significant difference between hybrid solid/liquid
or liquid phase assays inmeanGADA titer ranks assigned to
a subset of T1D sera (IDS285, IDS301, IDS319, and
IDS325; Mann–Whitney test: all P 0.0001).
CONCORDANCE OF AUTOANTIBODY UNITS
The concordance of arbitrary units assigned to cases was
assessed across assays expressing results in WHO units.
These included bridge-ELISAs, all commercial assays using
standards calibrated against theNational Institute ofBiolog-
ical Standards and Control 97/550 WHO reference serum
(14), and a subset of RBA and LIPS using theNIDDKDK
standards, also calibrated against the WHO reference se-
rum. Across all assays, interassay concordance of WHO
units was relatively low with an OCCC of 0.4870.
After assay stratification according to antibody/antigen
binding in hybrid solid/liquid phase or liquid phase, con-
cordance of antibody titers increased across liquid phase as-
Fig. 2. Performance of GADA assays in IASP2018.
Shown are the pAUC95 of each assay (gray filled dots) and the
probability density estimates of the pAUC95 distribution. Assays
are grouped by format and its variants and the groups sorted ac-
cording to their median pAUC95. The dashed line marks the me-
dian pAUC95 of all assays.
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says adopting the NIDDK calibrators (OCCC  0.82)
compared with bridge-ELISAs (OCCC 0.45) (Fig. 5B).
Stratification of assays confirmed a significant differ-
ence between hybrid solid/liquid or liquid phase assays in
the GADA titers assigned to a subset of T1D sera
(IDS285, IDS301, IDS319, and IDS325) (Mann–
Whitney test: P 0.0001, P 0.0011, P 0.0001, and
P  0.0008, respectively) (Fig. 5C).
Discussion
Workshops aimed at the standardization of T1D-
associated autoantibodies were originally established
by an international community of researchers trying to
address early discrepancies in results between labora-
tories measuring islet cell antibodies (28, 29 ). The
success of this initiative led to the recognition of the
Fig. 3. Tile map of GADA-positive (dark gray) or -negative (light gray) scores assigned by laboratories to cases.
Assays are grouped by format and its variants and the groups sorted according to their median pAUC95. Cases are ordered by median GADA
titer rank. A cumulative score of individual Ig class results was added for lab 1306 in the ECL group. Cases with distinctive patterns discussed
in the text are indicated by a black triangle.
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crucial role of assay format and protocols in determin-
ing the results of T1D immunoassays (30 ) and to the
implementation of a harmonization and assessment/
validation program for all major T1D autoantibodies.
Following themolecular identification of GAD65 as
a major T1D autoantigen, harmonization workshops of
GADA measurement accompanied the continuous de-
velopment, testing, and validation of a variety of GADA
immunoassays (31 ). Early interlaboratory comparison
studies led to the emergence of the liquid phase immu-
noprecipitation RBA as a widely implemented de facto
gold standard for GADA measurement (32 ).
Fig. 4. Tile map of GADA-positive (dark gray) or -negative (light gray) scores assigned by laboratories to controls.
Assays are grouped by format and its variants and the groups sorted according to their median pAUC95. Omitted are 40 controls negative in
all assays. A cumulative score of individual Ig class resultswas added for lab 1306 in the ECL group. Controlswith distinctive patterns discussed
in the text are indicated by a black triangle.
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Fig. 5. Analysis of GADA titers’ concordance in IASP2018.
(A), GADA titer ranks of each case in different assays (circles, filling is proportional to pAUC95). The black line shows the median rank of all
assays. (B), Boxplots of GADA WHO units in each case. Assays are grouped by binding phase (dark gray: hybrid solid/liquid all bridge-ELISA
assays; light gray: liquid, include ECL, LIPS, and RBA assays). (C), Enlargement showing samples with significant differences in WHO units
between assay groups. Cases selected in (C) are indicated in (A) and (B) by a black triangle.
IASP2018 GAD65 Autoantibody Interlaboratory Comparison
Clinical Chemistry 65:9 (2019) 1149
RBAs not only repeatedly demonstrated good sensi-
tivity and specificity in several interlaboratory compari-
sons (33 ) but also allowed laboratories to produce radio-
labeled GAD65 using a simple in vitro system and,
because in RBA antigen/antibody binding occurs in liq-
uid phase, assuaged the concern for the preservation of
GADA conformational epitopes without the disruption
often associated with antigen adsorption to a solid phase
(34 ).
The IASP2018 interlaboratory comparison study
saw the continued implementation of the RBA format by
the majority of laboratories, together with an expanded
adoption of alternative nonradioactive formats, allowing
for a comprehensive comparison between classical RBA
and other assay formats in terms of diagnostic, rather
than analytical, sensitivity, specificity, accuracy, concor-
dance, and performance.
Regarding the analysis of GADA assay performance
in IASP2018, in addition to calculating the ROC-AUC
curve, possibly the most widely used metric of a diagnos-
tic test performance, we evaluated the pAUC95. This
approach improves one of the major limitations and con-
founders of using the total ROC-AUC, i.e., the inclusion
in the analysis of regions of low assay specificity that are
not clinically relevant (12 ).
The characteristics of RBAs submitted to IASP2018
showed the presence of several alternative protocols dif-
fering with regard to assay buffers, washing method (i.e.,
centrifugation vs filtration), amount of test serum and
antigen, radiolabel (35S, 125I, 3H), and the use of full-
length or truncated GAD65 antigens (24–26). Unsur-
prisingly, RBAs presented a large degree of variability in
performance, with only a few RBAs using protocols de-
veloped in-house achieving a pAUC95 above the median
of all assays.
Among these protocol variables, the use of truncated
GAD65 antigen corresponding to amino acids 96 to 585
of the full-length protein was associated with better
pAUC95 compared with most RBAs using full-length
GAD65 in both RBAs and LIPS assays, another
immunoprecipitation-based format.
In IASP2018, the second most widely adopted im-
munoassays were commercial bridge-ELISAs. Bridge-
ELISAs showed the most homogeneous and highest
pAUC95 of all assays, save for the novel PCR-based
ADAP format, and proved more sensitive and specific
overall than most other assays, with the few positive
scores discrepant with those of high-performance RBAs
and LIPS assays, essentially limited to low titer GADA
samples.
We then reassessed positive scores after applying a
threshold based on a common predefined specificity of
95% to all assays, a threshold that, although not ideal if
applied to population screening, facilitated comparisons
across this limited sample set. This reanalysis showed that
discrepancies in low titer GADA cases were resolved in
the majority of LIPS assays and RBAs, suggesting that
most liquid phase assays in IASP2018 generally ad-
opted more conservative thresholds compared with the
bridge-ELISA.
The consistent detection by some RBAs and LIPS
assays of slightly increased antibody binding in some
specific blood donor sera from the IASP2018 sample
set suggests that threshold selection in these assays
might have been driven by the presence of low, non–
disease-specific antigen binding in some local control
samples. Based on previous publications, it can be
speculated that at least part of this binding might be
attributed to low affinity antibodies (25, 35 ).
The comparison of quantitative GADA results in
IASP2018 was complicated by the implementation of a
variety of local nonstandardized arbitrary units and cal-
culation algorithms to express results in place of the in-
ternational units endorsed by the WHO. Previous work-
shops addressed this source of interassay variability by
distributing the WHO standard serum and encouraging
reporting of GADA in WHO units. Because the WHO
reference consists of a strongly autoantibody-positive hu-
man serum and constitutes an intrinsically finite re-
source, its distribution was meant to be used for recali-
bration of local standards followed by conversion of local
to WHO units. However, after encouraging preliminary
results (36 ), further analyses did not confirm the same
level of concordance and reproducibility of WHO units
across laboratories (37 ). This prompted the design of a
common protocol, including an alternative set of GADA
serum standards calibrated against theWHO serumwith
the aim of harmonizing RBAs used by NIDDK-
sponsored consortia (23 ).
In IASP2018 the majority of assays reporting results
inWHO units consisted of bridge-ELISAs, whereas only
2 RBAs using a protocol developed in-house did so.
NIDDK standards were used by only 3 laboratories, and
these submitted results for RBAs using the NIDDK har-
monized protocol and/or LIPS assays.
Overall, although IASP2018GADA assays showed a
reasonable interassay agreement of GADA titer ranks
among the assays usingWHOunits, at least in cases if not
in control individuals, we observed a relatively lower con-
cordance of attributedGADA titers, particularly in a sub-
set of cases, despite the use of standardized protocols and
centrally prepared calibrators.
Moreover, a dichotomy in GADA titers attributed
to selected sera was evident when assays were grouped
according to antigen/antibody binding phase into hybrid
solid/liquid or just liquid phase assays. Although the un-
derlying reason for this behavior remains to be clarified,
multiple potential causes can be hypothesized, like
epitope alterations following the addition of tags (e.g.,
biotin residues in the bridge-ELISA or luciferase enzyme
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in LIPS), subtle differences in primary amino acid se-
quence, posttranslational modifications in different ex-
pression systems, and the adsorption of antigens onto
solid surfaces in the bridge-ELISA. The frequency of this
phenomenon remains to be ascertained along with its
potential impact, if any, on autoantibody-based screen-
ing strategies, which are currently mostly based on RBAs.
Several novel immunoassays were submitted to
IASP2018, a development likely spurred by the continu-
ous legislative and logistic pressure against the use of ra-
dioactive substances and the expected future implemen-
tation of antibody-based population screening programs
for T1D. Among these assays, the PCR-based ADAP
assay achieved both high sensitivity and perfect specific-
ity, whereas the rest showed variable performance that in
some cases was dramatically inferior to that of more ma-
ture formats.
In conclusion, the IASP2018 results depict the
field of GADA measurement as both mature, with
numerous assays achieving high performance, but also
in relative flux, with the active development and de-
ployment of novel immunoassays dispensing alto-
gether with the need for radio isotopic tracers. We
believe that these results confirm the usefulness of har-
monization programs, not only as providers of unbi-
ased diagnostic performance assessment to partici-
pants but also as an arena in which research
laboratories and companies can learn valuable lessons
for improving immunoassays for T1D autoantibodies.
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